Study wrapper · #63
Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy.
Editor's note
Same rat “occlusion/occlusion-like syndrome” program, this time triggered by a high dose of the antiarrhythmic sotalol (80 mg/kg). Researchers report that sotalol produced brain, heart, lung, liver, kidney and gastrointestinal lesions, severe bradycardia, widespread clotting and characteristic pressure disturbances, and that BPC-157 (10 µg or 10 ng/kg) given after the drug was associated with counteraction of these effects, again attributed to azygos-vein collateral activation. The sotalol dose used is supratherapeutic, so this is a model of extreme drug toxicity rather than clinical dosing, and the endpoints are acute (180 min) gross and microscopic findings. As throughout this series, the results are consistent and dramatic but originate largely from one laboratory whose lead holds BPC-157 patents, with no independent human data. Read as a mechanistic signal only. BPC-157's US status is removed from the FDA Category-2 list, pending review. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
This was an acute experiment in rats. Researchers gave a very high dose of sotalol — a heart-rhythm drug — which the study reports caused serious problems: a very slow heart rate, clots throughout the body, abnormal blood pressures, and congestion or damage in the brain, heart, lungs, liver, kidney and gut. Some rats then received BPC-157, a synthetic peptide, either 5 or 90 minutes later. The study reported that BPC-157 reduced or eliminated many of these effects, including heart congestion, clots and the pressure abnormalities, which the authors link to blood being rerouted through a backup vein. Animals were followed for about three hours, and the sotalol dose was far higher than a normal medical dose. Because this is a short animal study using an extreme drug dose, it points to a possible biological effect rather than proof of benefit in humans; human research would be needed. The abstract does not report specific side effects of the peptide.